BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24552543)

  • 1. Novel biomarkers in heart failure: usefulness in clinical practice.
    Siasos G; Tousoulis D; Oikonomou E; Kokkou E; Mazaris S; Konsola T; Stefanadis C
    Expert Rev Cardiovasc Ther; 2014 Mar; 12(3):311-21. PubMed ID: 24552543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using biomarkers to "guide" heart failure management: current perspectives and future directions.
    Motiwala SR; Januzzi JL
    Cardiol Rev; 2013; 21(3):127-34. PubMed ID: 23032578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
    Green SM; Green JA; Januzzi JL
    Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain natriuretic peptide in heart failure and beyond.
    Mowla MM; Bustami BB
    Saudi Med J; 2006 Oct; 27(10):1457-61. PubMed ID: 17013463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State of the art: using natriuretic peptide levels in clinical practice.
    Maisel A; Mueller C; Adams K; Anker SD; Aspromonte N; Cleland JG; Cohen-Solal A; Dahlstrom U; DeMaria A; Di Somma S; Filippatos GS; Fonarow GC; Jourdain P; Komajda M; Liu PP; McDonagh T; McDonald K; Mebazaa A; Nieminen MS; Peacock WF; Tubaro M; Valle R; Vanderhyden M; Yancy CW; Zannad F; Braunwald E
    Eur J Heart Fail; 2008 Sep; 10(9):824-39. PubMed ID: 18760965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BNP in the diagnosis and risk stratification of heart failure.
    Moe GW
    Heart Fail Monit; 2005; 4(4):116-22. PubMed ID: 16234898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natriuretic peptide-guided heart failure management.
    Troughton R; Michael Felker G; Januzzi JL
    Eur Heart J; 2014 Jan; 35(1):16-24. PubMed ID: 24216390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management.
    Palazzuoli A; Caputo M; CalabrĂ² A; Nuti R
    Minerva Cardioangiol; 2012 Apr; 60(2):183-94. PubMed ID: 22495167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in heart failure management.
    Isaac DL
    Curr Opin Cardiol; 2008 Mar; 23(2):127-33. PubMed ID: 18303525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biomarkers in heart failure: BNP and NT-proBNP].
    Ho CC; Liu CC
    Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes.
    Wiviott SD; de Lemos JA; Morrow DA
    Clin Chim Acta; 2004 Aug; 346(2):119-28. PubMed ID: 15256312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natriuretic peptides in heart failure and acute coronary syndrome.
    Gaggin HK; Januzzi JL
    Clin Lab Med; 2014 Mar; 34(1):43-58, vi. PubMed ID: 24507786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum biomarkers for heart failure.
    Jarolim P
    Cardiovasc Pathol; 2006; 15(3):144-9. PubMed ID: 16697927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure.
    van Kimmenade RR; Pinto YM; Bayes-Genis A; Lainchbury JG; Richards AM; Januzzi JL
    Am J Cardiol; 2006 Aug; 98(3):386-90. PubMed ID: 16860029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in heart failure. Does prognostic utility translate to clinical futility?
    Maisel A
    J Am Coll Cardiol; 2007 Sep; 50(11):1061-3. PubMed ID: 17825715
    [No Abstract]   [Full Text] [Related]  

  • 16. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients.
    Ellis KL; Cameron VA; Troughton RW; Frampton CM; Ellmers LJ; Richards AM
    Eur J Heart Fail; 2013 Oct; 15(10):1138-47. PubMed ID: 23696613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure biomarkers at point-of-care: current utilization and future potential.
    Christenson ES; Collinson PO; Defilippi CR; Christenson RH
    Expert Rev Mol Diagn; 2014 Mar; 14(2):185-97. PubMed ID: 24524847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in heart failure: natriuretic peptide testing.
    Rehman SU; Januzzi JL
    Panminerva Med; 2008 Jun; 50(2):139-51. PubMed ID: 18607337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure.
    Morello AM; Januzzi JL
    Expert Rev Mol Diagn; 2006 Sep; 6(5):649-62. PubMed ID: 17009901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.